New SEER data presented at AACR 2025 reveal a sharp decline in breast cancer mortality among women aged 20 to 49 across all ...

Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Olema Pharmaceuticals, Inc.’s OLMA share price has dipped by 5.94%, which has investors questioning if this is right time to buy.

Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 ...

Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering ...

Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 ...

Arvinas (NASDAQ:ARVN) stock drops 33% after announcing workforce cuts and trial removals, despite beating earnings ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

Breast cancer deaths among women ages 20-49 declined significantly between 2010 and 2020, according to a new study.